Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.63), $0.14 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.